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Depression, Neurocognitive Disorders,
and HIV in Prisons
Kristine M. Herfkens, Ph.D.*, Triangle
Neuropsychology Services, PLLC, Durham, NC

Mental health issues are difficult territory for
any healthcare provider. The situation
becomes exponentially more complex when
the patient is incarcerated and HIV is added to
the mix. The multifactorial etiology of mental
illness makes diagnosis and management of
these patients quite challenging. Treatment is
further complicated by factors such as potential medication side effects and interactions
and mental status changes due to opportunistic infections.
Psychiatric problems in the correctional setting
are more prevalent and often more severe
than seen in the general population (1). The
overall prevalence of psychiatric disorders
among inmates ranges from 30-70%; contributing to this high prevalence is co-occurring
substance use disorders (about 60%) and
neurocognitive disorders (about 50%). The
neurocognitive disorders often have multiple
etiologies, including acquired brain injury (ABI)
and the long-term consequences of substance
abuse. In addition, neurocognitive disorders
can complicate the management of other concurrent illnesses. Unfortunately, these disorders combine to reduce the likelihood that a
patient will adhere to treatment (2).
Factors contributing to the high prevalence of
psychiatric and neuropsychiatric disorders in
correctional populations should be carefully
considered when treating incarcerated
patients. Education, adaptive coping skills,
and a strong support network are essential for
protecting individuals from significant mental
health problems. Incarcerated men and
women tend to represent a marginalized sector of the general population, who also have
very poor social support networks and lower
levels of education.
Women often present with additional psychosocial factors. More than 60% of incarcerated women report histories of sexual abuse,
and an even greater number approaching
90% report physical abuse (3). This abuse history has been linked to a number of mental illnesses, including substance abuse, personal-
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ity disorders, affective disorders, and posttraumatic stress disorders. The extent of
severe, prolonged physical and sexual abuse
histories among incarcerated men is likely to
be similar and to contribute to the high prevalence of mental illness among them.

One of the most relevant
and underdiagnosed mental
health issues among inmates
with HIV is depression.
These primary (antecedent to HIV infection)
mental health issues play a critical role in
determining whether a person will become
infected with HIV, will adhere to a long term
medication regimen, and will engage in risk
factors for the development of other health
problems. Thus, managing mental illness is an
important part of providing HIV and medical
care to incarcerated populations.

Depression

One of the most relevant and underdiagnosed
mental health issues among inmates with HIV
is depression. Depression is common, potentially life threatening, and generally treatable.
Depression is several times more prevalent
among people with HIV than among the general population; prevalence of depressed
mood approaches 80% and 10-15% have
diagnosed major depression (4). Co-morbid
mental illness among HIV-infected prisoners is
concentrated in even higher numbers due to
co-existing substance use disorders among
prisoners. While the etiology of depression
may be multifactorial, including primary
depression, depression from substance
abuse, post-traumatic stress, or issues surrounding reasons for incarceration, nonetheless, depression must be diagnosed and effecContinued on page 2
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Depression...(continued from page 1)
tively treated to ensure adequate health outcomes.
Rates of self-reported depressed mood tend to be
highest immediately prior to HIV testing and while
waiting for results (5).
Additionally, for individuals undergoing HIV testing,
symptoms of depression may be enhanced, particularly in facilities where HIV testing is mandatory.
Psychiatric support and crisis intervention may be
most required at these times. As patients begin to
accommodate to their changing health status,
depressive issues may diminish over time, only to
reemerge at transition points in the disease.
Depression is thought to be related to damage to,
or alterations in the functioning of subcortical brain
structures (6). Increased rates of depression have
been seen in several neurologic disorders that differentially affect subcortical structures, such as
Parkinson's disease, Huntington's disease, and
HIV/AIDS. While depression (due to situational
factors) can certainly cause a patient to be distractible, irritable, forgetful, disorganized, apathetic
and slow, these behaviors may also be
symptomatic of the neurocognitive changes
associated with subcortical neurologic disorders.
Unfortunately, traditional treatments for depression
may be less than optimally effective in patients with
subcortical neurological disorders.

Cognitive Function

Although many healthcare providers may think of
the evaluation of cognitive functioning as being outside the purview of mental health, it is actually an
integral part of a mental health evaluation. Further,
it is often extremely difficult for physicians to distinguish the behavioral aspects of depression from
the consequences of subcortical neurocognitive
impairment. In patients with HIV, neurocognitive
disorders increase with the presence of psychiatric
symptoms, CD4<200, a history of poor medication
adherence, and a history of prior neurologic insults
(substance abuse, trauma, stroke, etc). Although
these patients frequently appear to be depressed,
uncooperative, and out of step with the environment, they may in reality be having difficulty comprehending and consistently tracking the changes
and demands of the prison setting. Thus, patients
with HIV may have symptoms that make differentiating depression from subcortical impairment more
challenging, especially since existing screening
tools are insensitive to measuring a difference.
Inmates with unrecognized cognitive impairment as
a result of HIV may be emotionally labile and
behaviorally unpredictable, inviting attacks from
other inmates and punishment/retaliation from correctional officers who fail to understand the behavioral impetus. They may receive punishment for
rule infractions that they were never entirely capable of understanding or remembering. They may
refuse medication, either intermittently or consistently, because of an inability to understand and/or
remember the consequences of non-adherence.
They may be asked to make decisions about their
Continued on page 4

Figure 1. The Center for Epidemiologic Studies Depression Scale
Experts who treat and study depression use a wide variety of tests and rating
systems to determine a person's level of depression. The Center for
Epidemiologic Studies Depression Scale (CES-D) is one of the most common
methods for allowing an individual to determine his or her depression quotient,
because it easy to understand, take, and score. This quick self-test measures a
patient's depressive feelings and behaviors during the past week. The CES-D developed by Lenore Radloff, while she was a researcher at the National
Institute of Mental Health - is an effective, time-honored tool that has become a
standard for identifying depression.
For the following 20 items,
please select the choice that best
describes how you have felt
over the past week:

Rarely or
none of the
time
(<1 day)

Some or a
little of the
time
(1-2 days)

Occasionally
or a moderate amount
of the time
(3-4 days)

Most or
all of the
time
(5-7 days)

1. I was bothered by things that
usually don't bother me.
2. I did not feel like eating;
my appetite was poor.
3. I felt that I could not shake off the
blues even with the help from my
family and friends.
4. I felt that I was not as good as
other people.
5. I had trouble keeping my mind on
what I was doing.
6. I felt depressed.
7. I felt that everything I did was
an effort.
8. I felt hopeless about the future.
9. I thought my life had been a failure.
10. I felt fearful.
11. My sleep was restless.
12. I was unhappy.
13. I talked less than usual.
14. I felt lonely.
15. People were unfriendly.
16. I did not enjoy life.
17. I had crying spells.
18. I felt sad.
19. I felt that people disliked me.
20. I could not get "going".
TO SCORE:
Step 1: For each answer, assign the following value:
0-Rarely or none of the time (<1 day)
1-Some or a little of the time (1-2 days)
2-Occasionally or a moderate amount
of the time (3-4 days)
3-Most or all of the time (5-7 days)

Step 2: Add the total scores and refer to
this scale:
G If the score is 22 or higher, the
patient may be suffering from a major
depression.
G If the score is 15 to 21, the patient
may be suffering from mild to moderate
depression.
G If the score is below 15, this test
does not indicate that the patient is
depressed.

Reference: Radloff, L.S. (1977). The CES-D scale: A self report depression scale for
research in the general population. Applied Psychological Measurement, 1, 385-401.
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Letter from the Editor
Dear Colleagues,
We are extremely pleased to bring you this issue of HEPP News on mental health! It covers
a very significant problem for correctional health care providers: the management of dual and
triple diagnosed patients (major psychiatric illness, substance use disorder and HIV). Cooccurring mental illness can interfere with both acceptance of and adherence to HIV medications. For such patients, HIV disease cannot be effectively treated without diagnosis and treatment of the mental illness. Unfortunatley, more than 50% of patients with mental illness are
either undiagnosed and/or untreated. This is likely to be more prevalent within our correctional systems. Though depression is the most common mental illness among our HIV-infected
inmates, we learn from our main article that the diagnosis may not be simple and that neurocognitive disorders and bipolar disorder may mimic depression. Treatment of depression in
these patients may have either no effect or adverse consequences if the proper diagnosis is
not made.
Management of dually diagnosed patients may result in a veritable pharmacy of prescribed
medications. In this issue, we try to ferret out potential drug interactions that clinicians must
address before administering psychiatric and HIV medications. Thus, it behooves psychiatrists
and HIV specialists alike to come to understand these drug interactions to avoid such dilemmas as presented in our Ask the Expert submission and to properly diagnose them when they
arise. Proper co-management of these conditions will result in improved outcomes for both HIV
disease and mental illness, and may have profound effects on recidivism if these patients are
properly managed within our correctional systems and linked to appropriate services upon
release.
After reviewing this issue, readers should be able to list which psychiatric medications can be
used in combination with antiretrovirals and describe the clinical management of depression
and other mental health disorders in HIV-infected patients.
In our next issue, we'll bring you news from the 8th Conference on Retroviruses and
Opportunistic Infections in Chicago, IL. January marks the second month of HEPP News continuing medical education (CME) credit online! Be sure to check it out at
www.HIVcorrections.org!
As always, we look forward to hearing from you!

The editorial board and contributors to HEPP
News include national and regional correctional
professionals, selected on the basis of their
experience with HIV care in the correctional
setting and their familiarity with current HIV
treatment. We encourage submissions, feedback, and correspondence from our readership.

Sincerely,

Frederick L. Altice, M.D.
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Depression...
(continued from page 2)

medical treatment or day to day lives that
they are no longer cognitively competent to
make. The implications of impaired decision
making ability in a prison setting, whether or
not it is due to HIV, are enormous due to the
unpredictability, complexity, and potential
for violence in correctional facilities. Thus,
any inmate with non-adherence to medications or health care should be carefully
screened for co-existing mental illness.

Screening for Mental
Health Disorders

Distinguishing depression from subcortical
neurocognitive impairment is difficult in a
clinical interview. Fortunately, brief screening instruments are available to quickly
identify patients with HIV who may be experiencing cognitive changes as well as affective disorders. The Mini Mental State
Examination (MMSE) (7) is widely used as
a quick cognitive screen, however, it
screens for cortical signs, rather than the
subcortical problems usually associated
with HIV-related changes. The Johns
Hopkins HIV Dementia Scale is an excellent alternative (See HEPPigram, page 6).
It is brief, easy to administer and interpret,
and freely available on the Internet at
http://www.iapac.org/clinmgt/mh/demscale.html. It screens short term memory,
concentration, and processing speed.
While these areas may show some impairment in patients with moderate to severe
depression, the cut off for considering
dementia is sufficiently low to reduce the
probability of false positive results. Another
test is the Center for Epidemiologic StudiesDepression test (CES-D), which is shown in
Figure 1. In general, screening should not
occur immediately after intake into the facility as substance abuse or reaction to incarceration may overestimate the number of
individuals with depression.
Regardless of whether HIV-infected prisoners have depressed affect secondary to
depression or impaired neurocognitive
changes, a trial of antidepressant therapy is
indicated. In general, a trial with selective

visit HEPP News online at www.hivcorrections.org
Table 1. Criteria for Manic Episode
A person is having a manic episode if experiencing a distinct period of abnormally
and persistently elevated, expansive or irritable mood, lasting at least one week or if
hospitalization is necessary. During the period of mood disturbance, three or more
of the following symptoms have persisted (four if the mood is only irritable):
1. inflated self-esteem or grandiosity
2. decreased need for sleep
3. more talkative than usual or pressure to keep talking
4. flight of ideas or subjective experience that thoughts are racing
5. easily distractible
6. increase in goal-directed activity (either socially or sexually) or
psychomotor agitation
7. excessive involvement in pleasure activities that have a high potential for
painful consequences (e.g., illegal activities, sexual indiscretions, buying sprees)
The symptoms must not meet criteria for a Mixed Episode, the mood disturbance
must be significantly severe to cause impaired impairment in social functioning, and
may not be due to the direct physiological effects of a substance (illicit drugs,
medications [e.g. SSRIs], or a general medical condition.
Reference: Diagnostic and statistical manual of mental disorders : DSM-IV, Fourth Edition.
Washington, DC : American Psychiatric Association, 1994.

serotonin reuptake inhibitors (SSRIs) is
likely to provide the best attempt at treatment. This class of drugs have few interactions with existing antiretrovirals (see HIV
101, page 7) and unlike tricyclic antidepressants, tend not to suppress cognitive
function.

Other mental Illnesses

Other conditions to be considered among
HIV-infected inmates who present with a
depressed mood or evidence of behavioral
problems include bipolar disorder and
schizophrenia. One study found that 24.3% of all inmates have bipolar disorder,
and 2.3-3.9% of all inmates are schizophrenic (8). In their discussion, the authors
suggest these numbers may be underestimates. This condition, if misdiagnosed and
treated with antidepressants rather than
mood stabilizing medications, may result in
episodes of mania that may lead to behavioral infractions or inability to adhere to
medication regimens. (See Table 1) In
some cases, the symptoms may be subtle.
Moreover, some patients with thought disorders (e.g. schizophrenia) go clinically undetected because these individuals have

become quite skilled at "covering" their
mental illness. (For an indepth review of
other mental illnesses, see reference 2,
Stevens et al, 2000.)

Conclusion

The range of psychiatric disorders that are
seen in a correctional population is broad.
The prevalence of all psychiatric disorders
is higher in an incarcerated population than
in the general population (1) , and some
disorders are even more likely in an HIVinfected population. Depression is the most
frequently encountered psychiatric disorder, both in and out of prison. Treatable and
common, depressive symptoms also suggest potential additional complications in
HIV-infected individuals. The symptoms of
depression can overlap with and mimic the
signs of subcortical impairment that is seen
in HIV patients. In order to effectively treat
symptoms, manage behavior, and promote
optimal autonomy in the correctional setting, physicians must begin to erase the
imaginary boundary between the mental
health and neurocognitive consequences of
this complex disease.

*Speakers Bureau: Bristol-Myers Squibb
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Managing the Patient with Triple Diagnosis

by Frederick L. Altice, M.D.*

Case:
R.V is a 32 year-old female prisoner who was diagnosed with HIV infection in 1994. In 1996, her CD4 was 454 and HIV-1 RNA was
78,000 copies/mL. She acquired HIV from intravenous drug use and was using 20 bags of heroin and cocaine per day. Since 1996
she has served four prison terms, during which she had repeatedly refused ART. Her brief previous incarcerations (one to three
months) were associated with multiple disciplinary actions and the HIV specialists noted she had "paranoid" attitudes about HIV and
ART. She had repeatedly denied auditory or visual hallucinations.
Most recently, she was sentenced to 18 months. Her CD4 has now decreased to 90 and her HIV-RNA is 242,000 copies/mL. During
the latest admission, she was fully evaluated by a psychiatrist and diagnosed with bipolar disorder. She was treated with valproic acid
(VPA) and stabilized on a therapeutic dose of 750 mg TID; her VPA level was 76 mg/dl. Six weeks later, she agreed to initiate ART.
After starting TMP/SMZ, she started stavudine (D4T) 40mg BID, abacavir (ABC, Ziagen) 300mg BID, ritonavir (RTV, Norvir) 200mg
BID and indinavir (IDV, Crixivan) 800 mg BID. Three days later, she was brought for medical evaluation for inability to stand up, dizziness and double vision. On exam, she had significant lateral gaze nystagmus. She had no fevers, headaches, or other focal neurological findings. The patient was admitted to the medical infirmary where her VPA was stopped and found to be 152 mg/dl (therapeutic
50 to 100 mg/dl). Her VPA level returned to a therapeutic level after four days and she was changed to lithium to avoid any further
drug interactions.
Discussion:
This is an extremely interesting case for three reasons:
1) her undiagnosed co-morbid mental illness resulted in delay
of treatment of her HIV disease for four years;
2) ART was initiated in a patient with advanced disease; and
3) there was significant drug interaction between psychiatric
and HIV medications.

Communication between the
mental health and HIV team
was crucial to maximize benefit for
this patient with triple diagnosis (mental
illness, substance use disorder, and HIV).
Co-morbid mental illness among HIV-infected inmates is
extremely prevalent and ranges from 40-60%. As much as
50% of the mental illness is undiagnosed and therefore
untreated. As evidenced in this patient, ART was delayed by
four years due to undiagnosed and untreated bipolar disorder.
The selection of a potent three-drug combination (a pharmacologically enhanced protease inhibitor) in this patient with
advanced disease seems appropriate because the CD4 count
is less than 100 copies/mL and the HIV viral load is greater
than 100,000 copies/mL. Fortunately, none of the agents
used develop resistance rapidly if adherence were poor or the
combination was not potent enough.

In this patient, nevirapine (NVP, Viramune) and efavirenz
(EFV, Sustiva) would have induced CYP3A4, the major metabolic pathway for VPA, and resulted in subtherapeutic levels.
In R.V.'s case, the protease inhibitors, particularly ritonavir,
inhibited CYP3A4 and resulted in supratherapeutic VPA levels
and increased VPA toxicity.
It is unlikely that this patient's neurological findings were related to a direct effect of a CNS opportunistic infection. Toxoplasma reactivation may occur with immune reconstitution,
however this occurs weeks to months after initiation of ART.
The timing of ART therapy three days prior makes a drugrelated event more likely.
In this case, two other options might have avoided this scenario of increased VPA levels. First, the patient could have
been started on D4T, ABC, and nelfinavir (NFV, Viracept) and
had therapy intensified if viral load exceeded 400 copies/mL
at three months. NFV is much less likely than RTV to inhibit
CYP3A4 and result in toxic VPA levels. Second, the patient
could have been changed to an alternative treatment for bipolar disorder (e.g. lithium, olanzapine) and then initiated on the
D4T/ ABC/ RTV/ IDV as done with this patient.
In either case, communication between the mental health and
HIV teams was crucial to maximize benefit for this patient with
triple diagnosis (mental illness, substance use disorder, and
HIV). The challenge that lies ahead is coordination of care for
this person returning to the community.

*Speakers Bureau: Agouron Pharmaceuticals, Abbott Pharmaceuticals, Roxane, Bristol-Myers Squibb, DuPont, GlaxoSmithKline, Merck, Roche.

CME is Now Available Online at www.hivcorrections.org:

HEPP readers are now able to take HEPP News' continuing medical education (CME) tests online at
http://www.HIVcorrections.org. Any internet browser will enable you to take the HEPP News CME tests every month.
Your test results will be registered with the Brown Medical School Office for Continuing Medical Education. When you
pass the test, you can either download your CME certificate from the website or request Brown to send the certificate in
the mail. Try it out this week!
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The HIV Dementia Scale

This tool screens short term memory, concentration, and processing speed. While these areas may show some impairment in
patients with moderate to severe depression, the cut off for considering dementia is sufficiently low to reduce the probability of false
positive results. The maximum score is 16. A score of 10 or less suggests HIV dementia.

SCORE

MAXIMUM

TEST
Memory-registration: Give the patient four words (dog, hat, green, peach) in four seconds
and ask for immediate recall. Repeat words if patient does not recall them immediately. Tell
patient you will ask for recall of the words again a bit later.

4

Attention: Hold both hands up at patient's shoulder width and eye height and ask patient to
look at your nose. Move the index finger of one hand and instruct patient to look at the finger
that moves, then look back to your nose. Practice until patient is familiar with task. Then
instruct patient to look at the finger that is not moving. Practice until patient understands task.
Perform 20 trials. An error is recorded when the patient looks toward the finger that is moving. Score: <3 errors = 4; 4 errors = 3; 5 errors = 2; 6 errors = 1; >6 errors = 0

6

Psychomotor speed: Instruct patient to write the letters of the alphabet (upper case) with a
Measure time in seconds using a stop watch. As a pretest, ask patient to say the letters of
the alphabet out loud. If unable to do so, ask patient to count from 1 to 26 out loud. If the
patient is unable to count correctly, ask patient to write numbers from 1 to 20 and time.
Convert the score in seconds to a numerical value. Score: <21 sec = 6; 21.1 to 24 sec = 5;
24.1 to 27 sec = 4; 27.1 to 30 sec = 3; 30.1 to 33 sec = 2; 33.1 to 36 sec = 1; >36 sec = 0

4

Memory-recall: Five minutes after the start of the test, ask patient to recall the four words.
Score: Give 1 point for each word spontaneously recalled. For words not recalled, prompt
with asemantic clue as follows: animal (dog); piece of clothing (hat); color (green); fruit
(peach). Give 0.5 point for each word recalled correctly after prompting.

2

Constructional: Ask patient to copy a 3-D cube as precisely and quickly as possible. Convert
the raw score to a numerical score. Score: <25 sec = 2; 25 to 35 sec = 1; >35 sec = 0

This test was developed by Johns Hopkins University and is available on the web at
http://www.iapac.org/clinmgt/mh/demscale.html.

Resources
Multi-Health Specialities (MHS) produces a comprehensive catalog of psychological test instruments, including the Becks
Depression scale and the CES-D. Call 800.456.3003 or write
MHS at 908 Niagara Falls Blvd., North Tonawanda, NY 141202060, 800.456.3003.

Mental Health Websites:
Mental Health Info Source
http://www.mhsource.com

International Association of Physicians in AIDS Care
http://www.iapac.org/index.html
Depression, Anxiety and Mental Health
http://www.thebody.com/mental.html
Substance Abuse and Mental Health Service Administration
http://www.samhsa.gov/
Mental Health: Knowledge Exchange Network (KEN)
http://www.mentalhealth.org

National Institute of Mental Health Center for Mental Health
Research on AIDS
http://www.nimh.nih.gov/oa/index.htm

HIV/AIDS Treatment Websites:
Harvard AIDS Institute
http://www.hsph.harvard.edu/hai/

National Library of Medicine Resources on HIV/AIDS
http://sis.nlm.nih.gov/hiv.cfm
HIV Insite
http://hivinsite.ucsf.edu/
AEGiS: The largest HIV/AIDS resource on the internet
http://www.aegis.com
The Body: An AIDS and
HIV information Resource
http://www.thebody.com

6
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BENZODIAZAPINE

MOOD
STABILIZING
AGENTS

ANTIPSYCHOTICS

Other
Agents

Tricyclics

Mixed Agents

Serotonin Reuptake Inhibitors
(SRIs or SSRIs)

Interactions Between HIV and Mental Health Medications

ANTIDEPRESSANTS

HIV 101

January 2001

MEDICATION (Brand Name)

INTERACTION

Fluoxetine (Prozac)

See * below. a, b, c

Citalopram (Celexa)

Could be affected by RTV, monitor for toxicity. Of SSRIs,
this agent is less likely to be affected by PIs.

Sertraline (Zoloft)

Side effects are similar to those noted for Prozac, but are
less severe due to shorter half-life. a, b, c

Paroxetine (Paxil)

Promotes sleep; initial dose is 20 mg/d; increase by 10mg
increments. Less likely to interfere with other medications
than other SRIs. d

Fluvoxamine (Luvox)

a, b, c

Venlafaxine (Effexor)

a, b

Buspirone (BuSpar)

G Nonbenzodiazepine-nonbarbiturate; dependence liability negotiable; increase dose 5mg q 2-4 days to effective
daily dose of 15-30mg.*
G Not likely to be affected by PIs or NNRTIs.

Amitryptyline (Elavil)

d

Doxepin (Sinequan)

d

Nortriptyline (Aventyl, Pamelor)

Titrate level (70-125mg/dL). promotes sleep. d

Desipramine (Norpramin)

Desipramine (<125 ng/dl). promotes sleep. d

Nefazodone HCl (Serzone)

a, b, c

Bupropion (Wellbutrin/Zyban)

Initial dose is 150mg bid; increase to 300mg/day after 3
days, as necessary. a, b, c

Haloperidol (Haldol)

d

Chlorpromazine (Thorazine)

d

Respiridone (Respirdal)

d

Imipramine (Tofranil)

d

Thioridazine (Mellaril)

d

Perphenazine (Trilafon)

d

Lithium

Not affected by PIs or NNRTIs

Olanzapine (Zyprexa)

a, b, d

Valproic Acid (Depakote, Divalproex)

a, b,c

Diazepam (Valium)

d, e

Clonazepam (klonopin)

b, d, e

Alprazolam (Xanax)

b, d, e

Temazepam (Restoril)

b, d, e

Lorazepam (Ativan)

b, d, e

*tetracycline, fluoroquinolones contraindicated in pregnancy

COMMENTS KEY:
a - potential $ levels by efavirenz (EFV),
nevirapine (NVP; clinical significance
unclear, monitor for sub-therapeutic effect
b - potential # levels by Protease
Inhibitors (PIs); clinical significance
unclear, monitor for toxicity
c - potential # levels of PIs and Nonnucleoside Reverse Transcriptase
Inhibitors (NNRTIs); clinical significance
unclear,
monitor for toxicity
d - possible # levels by ritonavir
e - Metabolites could be affected by PIs
and NNRTIs, clinical significance unclear.
Suggested start with reduced dosage and
titrate up.
* Major side effects are nausea, nervousness, insomnia, weight loss, dry mouth,
constipation; insomnia may be treated
with Desyrel 25-50mg hs.

Developed by HEPP staff.
References: Bartlett JG and Gallant JE. 2000-2001 Medical Management of HIV Infection. Johns Hopkins University, Baltimore, MD.
2000. Available at http://www.hopkins-aids.edu/publications/book/ch7_1std.html.
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Save the
Dates
Management of HIV/ AIDS in the
Correctional Setting: A Live
Satellite Videoconference Series
"Primary Care of the HIV-Infected
Incarcerated Patient"
January 30, 2001
12:30-3:30 p.m. EST
CME Credits Available
Call: 518.262.6864
Email: santosm@mail.amc.edu
www.amc.edu/patient/HIV/hiv.htm
(videoconference series)
Funding Opportunity: National
Partnerships for HIV Prevention
with a Focus on Business and
Labor, Youth at High Risk, and
Migrant Workers.
Applications due:
February 23, 2001.
Call: Julia Valentine at
888.472.6874
Visit: http://www.cdc.gov/od/
pgo/funding/01017.htm
25th Annual NCCHC Conference
November 2001
Abstract DEADLINE
is February 28, 2001.
Visit: www.ncchc.org
American Correctional Health
Services Multidisciplinary
Training Conference
March 15-18, 2001
Atlanta, Georgia
Call: 877.918.1842
Visit: www.corrections.com/
achsa/conferences.html

New at HEPP News!
We thank our readers for their
positive comments and helpful
suggestions on the HEPP
News Survey. You suggested,
and we've made, the following
changes:
G Continuing Medical
Education credits are
available online at
www.HIVcorrections.org.
G 24 archived issues of
HEPP News are now
available online.
G Topics like Hepatitis C and
TB are covered and written
specifically for the
correctional setting!
G You can receive HEPP
News via email every
month electronically.

visit HEPP News online at www.hivcorrections.org
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News Flashes
CDC warns: Use of Nevirapine for Post
Exposure Prophylaxis Associated with
Adverse Events
Serious adverse events have been attributed
to nevirapine (NVP, Viramune) regimens in
otherwise healthy, uninfected healthworkers
who experienced a needle stick while treating a potentially HIV-infected patient (CDC.
Serious Adverse Events Attributed to
Nevirapine Regimens for Postexposure
Prophylaxis After HIV Exposure - Worldwide,
1997-2000. MMWR 1/05/01; 49(51): 1153.)
Nevirapine has not been recommended for
PEP. Nevirapine is recommended, however,
to treat individuals infected with HIV and to
prevent vertical transmission of HIV from
mothers to their infants during birth, with the
different recommendations based on the "relative benefits and risks" of the drug. No serious adverse effects have been found in vertical transmission studies with nevirapine, and
UNAIDS supports the CDC's recommendation for using the drug to prevent such transmission.

Recent Evidence Supports HAART
Intitiation During Primary HIV Infection
According to the December issue of AIDS,
initiation of HAART during primary HIV infection results in more rapid and complete
immune reconstitution than when started
later. Australian researchers conducted a
prospective study of 58 treatment-naive individuals who received indinavir or nelfinavir
plus two nucleoside reverse transcriptase
inhibitors. Dr. Gilbert Kaufmann and colleagues found that at 12 months, the median
CD4 count increased from 470 to 758
copies/mL in patients with primary infection
compared with an increase from 204 to 310
copies/mL in chronically infected individuals.
Normal levels of CD4 cells were achieved in
93% and 37% of primary and chronically
infected individuals, respectively. Kaufmann
et al note, however, that longer followup will
be required to determine whether enhanced
immunological recovery translates into
improved long-term outcome. (AIDS
2000;14:2643-2651).

The December issue of Infection Control and
Hospital Epidemiology (2000;21:780-785)
published a study showing that side effects
from postexposure prophylaxis (PEP) for HIV
are common, although treatment toxicity is
rarely serious. Of the 449 patients for whom
six-week data were available, more than half
of the 197 people who discontinued PEP
reported doing so because of adverse
effects.

Italian Prisons Successful with DOT for
HAART
A recent letter to JAMA reported that directly
observed therapy (DOT) was well accepted
and improved adherence to HAART regimens among Italian prisoners. Italian
researchers selected nine Italian prisons in
which antiretroviral drugs are administered
by DOT (DOT schedule), and nine prisons in
which nurses leave all drugs with the patient
once a day (NDOT schedule). Eighty-four
HIV-infected intravenous drug users were
consecutively enrolled from April 1997 to
September 1998. All patients in the DOT
group showed a significant decrease in viral
load (>2 log) after therapy. Of these, 23
(62.1%) had a plasma HIV RNA level below
the detection limit compared with 16 patients
(34.0%) in the NDOT. In the DOT group, only
two patients (5.4%) had CD4 <200 106/L,
while 15 NDOT (31.9%) had CD4 cell
CD4<200 106/L. The authors assume that
the DOT group had 100% adherence to the
treatment regimen. The cost of implementing
DOT in this setting was low; according to the
authors, no additional staff was required to
administer this therapy. Ensuring adherence
to treatment regimens by DOT results in a
higher efficacy of HAART. (Babudieri S, Aceti
A, D'Offizi GP, Carbonara S, Starnini G.
Directly observed therapy to treat HIV infection in prisoners [letter] JAMA. 2000 Jul
12;284(2):179-80.)

BMS Issues Caution on D4T and DDI Use
in Pregnant Women
While the Food and Drug Administration
(FDA) conducts a review of the two products, Bristol-Myers Squibb has issued a
warning to AIDS doctors around the world
cautioning that two of its AIDS drugs, stavudine (d4T, Zerit) and didanosine (Videx, ddI),
should be used sparingly in pregnant women
after the deaths of three expectant mothers
who were taking the medications. Three
cases of fatal lactic acidosis were reported to
the FDA that occurred in pregnant women
taking Zerit and Videx in combination with
other drugs used to treat HIV. Although data
have suggested that women may be at
increased risk for the development of lactic
acidosis and liver toxicity, it is unclear
whether pregnancy potentiates these known
side effects. The complete FDA Talk Paper
can be accessed at
http://www.hivatis.org/atisnew.html.

Other News . . .
We have a new sign-up number, so tell your colleagues to sign up for HEPP News by calling
1.800.748.4336. (You can also sign up on the website at www. hivcorrections.org or by faxing
1.617.770.3339 or emailing hepp@corrections.net.)
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Self-Assessment Test for Continuing Medical Education Credit
Brown Medical School designates this educational activity for 1 hour in category 1 credit toward the AMA Physicians Recognition Award.
To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each of the questions. A
minimum of 70% of the questions must be answered correctly. This activity is eligible for CME credit through
Jan. 22, 2002. The estimated time for completion of this activity is one hour and there is no fee for participation.

CME is now available ONLINE at www.hivcorrections.org
1. Which of the following medications decrease levels of
efavirenz (EFV, Sustiva) and nevirapine (NVP, Viramune)?
a) Citalopram (Celexa)
b) Amitryptyline (Elavil)
c) Fluoxetine (Prozac)
d) Haloperidol (Haldol)
e) Buspirone (BuSpar)
f) None of the above
2. Which of the following classes of psychiatric medications
could be effected by ritonavir (RTV, Norvir)?
a) Serotonin Reuptake Inhibitors
b) Tricyclics such as Amitryptyline (Elavil) or
Doxepin (Sinequan)
c) Some mood stabilizing agents such as valproic acid
d) b and c
e) a and b
f) None of the above
3. What percentage of HIV-infected inmates also have a mental
health disorder?
a) 5-10%
b) 10-15%
c) 25-40%
d) 40-60%
4. Which of the following regimens would be appropriate for an
HIV-infected patient who is taking valproic acid (Depakote)?
a) stavudine (D4T), abacavir (ABC, Ziagen), ritonavir
(RTV, Norvir) and indinavir (IDV, Crixivan).
b) nevirapine (NVP, Viramune) and efavirenz (EFV, Sustiva)
c) D4T, ABC, and nelfinavir (NFV, Viracept)
d) b and c
e) None of the above.
5. The likelihood that a neurocognitive disorder is present
increases with the presence of which of the following conditions?
a) CD4 <200 copies/mL
b) poor adherence to medications
c) a history of substance abuse
d) stroke
e) all of the above
f) None of the above

6. Which of the following statement are true about patients with
HIV?
a) Depression is more common among HIV-infected patients
than non-infected patients.
b) Traditional treatments for depression may be inefficient in
patients with subcortical neurological disorders.
c) A history of sexual or physical abuse may be linked to
mental health disorders.
d) The etiology of depression is frequently multifactorial.
e) b and c
f) All of the above

HEPP News Evaluation
5 Excellent

4 Very Good

3 Fair

2 Poor

1 Very Poor

1. Please evaluate the following sections with respect to:
educational value
clarity
Main Article
5 4 3 2 1
5 4 3 2 1
HIV 101
5 4 3 2 1
5 4 3 2 1
Ask the
Expert
5 4 3 2 1
5 4 3 2 1
Save the
Dates
5 4 3 2 1
5 4 3 2 1
2. Do you feel that HEPP News helps you in your work?
Why or why not?
3. What future topics should HEPP News address?
4. How can HEPP News be made more useful to you?
5. Do you have specific comments on this issue?

BROWN MEDICAL SCHOOL  OFFICE

OF CONTINUING MEDICAL EDUCATION  BOX G-A2  PROVIDENCE, RI 02912
The Brown Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical
education activities for physicians.

The use of the Brown Medical School name implies review of the educational format and material only. The opinions, recommendations
and editorial positions expressed by those whose input is included in this bulletin are their own. They do not represent or speak for the
Brown Medical School.

For Continuing Medical Education credit please complete the following and mail or fax to 401.863.2660 or
register online at www.hivcorrections.org. Be sure to print clearly so that we have the correct information for you.
Name __________________________________________________________________ Degree
Address

____________________

____________________________________________________________________________________________

____________________________________________________________________________________________________
City

____________________________________________________ State

________ Zip ________________________

Telephone ________________________________________________ Fax ______________________________________

